12 Jan
Hyperparathyroidism in multiple endocrine neoplasia type II A: RET, hyperparathyroidism and genetic testing
A germ-line RET point mutation has been described in over 92% of MEN 2 families. Therefore, DNA testing for RET mutations has been proposed as a confirmative test in patients with a clinical suspicion of MEN 2 syndrome and as a predictive test in asymptomatic patients who are clinically at risk. The high sensitivity and [...]